• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Endari (L-glutamine oral powder)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Endari (L-glutamine oral powder)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Endari (L-glutamine oral powder) reduces oxidant damage to red blood cells by improving the redox potential of nicotinamide adenine dinucleotide (NAD), a coenzyme that has been identified as the primary regulator of oxidation. 

    Endari is specifically indicated to reduce the severe complications of sickle cell disease (SCD) in adult and pediatric patients age 5 and older.

    Endari is supplied as a powder for oral administration.

     

     

    Clinical Results

    FDA Approval

    The FDA approval of Endari was supported by efficacy data from a 48-week randomized, double-blind, placebo-controlled, multicenter Phase IIIclinical trial evaluating the effects of Endari, prescription grade L-glutamine, as compared to placebo on 230 adults and children with SCD. The results demonstrated that Endari reduced the frequency of sickle cell crises by 25% and hospitalizations by 33%. Additional findings showed a decrease in cumulative hospital days by 41% and lower incidence of ACS by more than 60%. 

    Side Effects

    Adverse effects associated with the use of Endari may include, but are not limited to, the following:

    • constipation
    • nausea
    • headache
    • abdominal pain
    • cough
    • pain in extremity
    • back pain
    • chest pain (non-cardiac)

    Mechanism of Action

    Endari (L-glutamine oral powder) reduces oxidant damage to red blood cells by improving the redox potential of nicotinamide adenine dinucleotide (NAD), a coenzyme that has been identified as the primary regulator of oxidation. 

    Additional Information

    For additional information regarding Endari or sickle cell disease, please visit http://www.emmausmedical.com

    Approval Date: 2017-07-01
    Company Name: Emmaus Life Sciences
    Back to Listings

    Upcoming Events

    • 15Sep

      Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis

    • 21Sep

      The FDA’s Focus on Clinical Data Integrity Throughout Product Development and Approval

    • 16Oct

      WCG MAGI's Clinical Research Conference 2022 West

    • 16Nov

      17th Annual FDA Inspections Summit

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Options-360x240.png

      Cancer Patients Signal Interest in Less Travel, More Remote Trial Options

    • SurveywBlueBackground-360x240.png

      New Study Shows Trends in Funding, Racial Balance Amidst COVID-19

    • Complexity-360x240.png

      Rising Trial Complexities Create More Payment Problems, Frustrations for Sites

    • Challenge-360x240.png

      BYOD Trials Growing in Popularity, But Unique Tech Challenges Remain

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing